# New Congressional Bill Would Let State Agencies Provide Marijuana for Research, Backed by $150M > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/new-congressional-bill-marijuana-research-access/ > **Published:** 2026-04-22T17:04:09-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:15:10-04:00 > **Clinical Summary:** Explore the new congressional bill marijuana research aims to expand state-licensed cannabis access for clinical studies with $150 million funding. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic ResearchPolicy[Evidence-Based Medicine](https://cedclinic.com/digital-health-expertise-modern-challenge/)Federal RegulationClinical Practice Why This Matters Federal research restrictions have created a decades-long evidence gap in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), forcing clinicians to make treatment decisions with limited high-quality data. Expanding research access through state-licensed sources could accelerate the generation of clinically relevant safety and efficacy data that physicians desperately need. Clinical Summary Congressional legislation proposes allowing state-licensed cannabis operators to provide research material, breaking the current federal monopoly on research-grade cannabis. The bill includes $150 million in funding to support expanded research efforts. This represents a potential shift from the current system where researchers must use limited federal sources that may not reflect commercially available products patients actually use. The legislation could enable studies using cannabis products that mirror real-world patient access. Dr. Caplan’s Take “We’ve been practicing [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) with one hand tied behind our backs due to research restrictions. If this passes, we might finally get data on the products our patients are actually using, rather than making clinical decisions based on studies of government-grown cannabis that bears little resemblance to dispensary products.” Clinical Perspective 🧠 Clinicians should understand that current [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) often uses federal cannabis that differs significantly from state-licensed products in potency, cannabinoid profiles, and cultivation methods. This legislation could bridge that gap, potentially leading to more clinically relevant research within 3-5 years. Until then, clinicians must continue making evidence-based decisions with existing data while acknowledging these limitations to patients. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20New%20Congressional%20Bill%20Would%20Let%20State%20Agencies%20Provide%20Marijuana%20For%20Research%2C%20...%20%40drcaplan&url=https%3A//www.marijuanamoment.net/new-congressional-bill-would-let-state-agencies-provide-marijuana-for-research-backed-by-150-million-in-new-funding/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.marijuanamoment.net/new-congressional-bill-would-let-state-agencies-provide-marijuana-for-research-backed-by-150-million-in-new-funding/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20New%20Congressional%20Bill%20Would%20Let%20State%20Agencies%20Provide%20Marijuana%20For%20Research%2C%20...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.marijuanamoment.net/new-congressional-bill-would-let-state-agencies-provide-marijuana-for-research-backed-by-150-million-in-new-funding/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.marijuanamoment.net/new-congressional-bill-would-let-state-agencies-provide-marijuana-for-research-backed-by-150-million-in-new-funding/](https://www.marijuanamoment.net/new-congressional-bill-would-let-state-agencies-provide-marijuana-for-research-backed-by-150-million-in-new-funding/) Table of Contents - [FAQ](#FAQ)[What type of clinical relevance does this cannabis news have?](#What_type_of_clinical_relevance_does_this_cannabis_news_have) - [What topics does this cannabis research cover?](#What_topics_does_this_cannabis_research_cover) - [Why is this cannabis news considered significant for clinicians?](#Why_is_this_cannabis_news_considered_significant_for_clinicians) - [What does the CED Clinical Relevance rating system indicate?](#What_does_the_CED_Clinical_Relevance_rating_system_indicate) - [How should healthcare providers use this cannabis information?](#How_should_healthcare_providers_use_this_cannabis_information) - [Related](#Related) ## FAQ #### What type of clinical relevance does this cannabis news have? This article has been rated as having “Notable Clinical Interest” with a CED Clinical Relevance score of #70. It represents emerging findings or policy developments that are worth monitoring closely by healthcare professionals. #### What topics does this cannabis research cover? The article covers multiple important areas including research findings, policy developments, [evidence-based medicine](https://cedclinic.com/digital-health-expertise-modern-challenge/) applications, and federal regulation changes. These topics indicate comprehensive coverage of cannabis-related clinical and regulatory updates. #### Why is this cannabis news considered significant for clinicians? The classification as “Notable Clinical Interest” suggests this information could impact clinical practice or [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) decisions. Healthcare providers should stay informed about these developments as they may influence treatment protocols or regulatory compliance. #### What does the CED Clinical Relevance rating system indicate? The CED Clinical Relevance rating system helps healthcare professionals prioritize which cannabis-related news and research to focus on. A rating of #70 with “Notable Clinical Interest” designation means this information has meaningful implications for clinical practice. #### How should healthcare providers use this cannabis information? Healthcare providers should monitor these emerging findings and policy developments as they may affect patient treatment options or regulatory requirements. The evidence-based medicine focus suggests this information could inform clinical decision-making processes. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence US Representatives introduce the Higher Education Marijuana Research Act – MMJDaily Learn about the Higher Education Marijuana Research Act introduced by US representatives to expand [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) opportunities. Read More [Feds ease cannabis restrictions—and open options for researchers – KGUN 9](https://cedclinic.com/federal-cannabis-research-policy-changes/) Discover how federal easing of cannabis restrictions is opening new research possibilities for scientists and clinicians. [Explore Article](https://cedclinic.com/federal-cannabis-research-policy-changes/) [Missouri sets sights on establishing licensed cannabis research | News | missourian.com](https://cedclinic.com/state-licensed-cannabis-research-frameworks-missouri/) Missouri's efforts to establish licensed cannabis research programs highlight growing state-level initiatives in [cannabis science](https://cedclinic.com/biphasic-effects-of-cannabis/). [Learn More](https://cedclinic.com/state-licensed-cannabis-research-frameworks-missouri/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).